BioSpace News Archive

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2023, after the market close on Monday, November 13, 2023.

QIAGEN announced results for the third quarter and first nine months of 2023.

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it submitted an updated Investigational New Drug (IND) application for BT-600 to the U.S. Food and Drug Administration (FDA) as planned.

Signifying a monumental step forward in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces that its Investigational New Drug (IND) application for SPX-303, a First-in-Class anti-LILRB2/PD-L1 bispecific antibody drug candidate, has been greenlighted by the U.S. Food and Drug Administration (FDA).

PaxMedica, Inc. announced that as a result of its 1-for-17 reverse stock split of its common stock that became effective at 8:03 a.m. Eastern Time on October 30, 2023, its common stock will begin trading on a split-adjusted basis with the open of the market on October 31, 2023.

Transpire Bio, a development-stage biopharmaceutical company, was joined by local and state elected officials and industry leaders to celebrate the opening of its new research facility and global headquarters in Weston.

Catalyst Biosciences, Inc. announced completion of the business combination with GNI Group Ltd. and related entities.

Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer.

Mustang Bio, Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the purchase and sale of 2,588,236 of its shares of common stock at a purchase price of $1.70 per share.

RetinalGeniX™ Technologies Inc., announced the launch of an Institutional Review Board for research on its DNA/GPS program.